Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Average Rating of “Hold” from Analysts

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) have been given an average recommendation of “Hold” by the seven ratings firms that are covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $17.25.

A number of equities research analysts recently weighed in on AUPH shares. Jefferies Financial Group raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the company from $10.00 to $21.00 in a research report on Friday, November 7th. Bloom Burton downgraded Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a report on Wednesday, November 5th. Leerink Partners cut Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and upped their target price for the company from $15.00 to $16.00 in a research report on Wednesday, December 3rd. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $15.00 price target (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a research report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, October 8th.

Institutional Trading of Aurinia Pharmaceuticals

Large investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. acquired a new position in Aurinia Pharmaceuticals in the third quarter valued at $48,000. MAI Capital Management acquired a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth about $39,000. State of Alaska Department of Revenue purchased a new position in shares of Aurinia Pharmaceuticals during the third quarter worth about $91,000. USA Financial Formulas acquired a new position in Aurinia Pharmaceuticals in the 3rd quarter valued at about $107,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in Aurinia Pharmaceuticals in the 2nd quarter valued at about $92,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Performance

Shares of Aurinia Pharmaceuticals stock opened at $16.25 on Friday. The company has a quick ratio of 5.17, a current ratio of 5.76 and a debt-to-equity ratio of 0.15. Aurinia Pharmaceuticals has a 52 week low of $6.55 and a 52 week high of $16.54. The firm’s 50 day moving average is $14.86 and its two-hundred day moving average is $12.03. The firm has a market capitalization of $2.14 billion, a P/E ratio of 29.02 and a beta of 1.42.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.07. The business had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $67.70 million. Aurinia Pharmaceuticals had a net margin of 29.28% and a return on equity of 25.19%. Research analysts forecast that Aurinia Pharmaceuticals will post 0.11 EPS for the current fiscal year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.